Pharmaceutical development blog posts

14 February, 2019

How commercialization of your drug can impact the cost of drug development

By Matthew Catley

How does a pharmaceutical company with no marketed products have a market capitalization of 1 billion dollars?  The answer to this question is probably quite complex, but ultimately the value investors place on a company is related to the commercial potential of the pipeline.  Ensuring you have a commercialization strategy that increases the chance of success for investors is key to obtaining the funding and will support the cost of your therapeutic development activities.

+ Read more
 

13 February, 2019

4 crucial factors to consider when choosing a preclinical CRO

By Carey Rooks

In recent years, the role preclinical contract research organizations (CROs) play has been evolving. Traditionally, CROs would provide study data reports for well-defined projects. Now however, they are a more intrinsic part of the drug development process for many companies by providing strategic support and guidance to help ensure the successful progression of compound.

+ Read more
 

13 February, 2019

3 reasons to engage a preclinical CRO earlier

By Carey Rooks

Preclinical drug development is inherently risky, with only one medicine being approved for every 10–20 candidates tested. The need to manage many moving parts, combined with increasing costs and the pressure to hit key milestones, means keeping a preclinical program on track can be a daunting task. But all is not lost, there is one crucial piece of the puzzle that can give you the competitive edge – utilizing a CRO’s scientific, operational and regulatory expertise at the very beginning of the preclinical stage to help design and carve your project plan.

+ Read more
 

28 January, 2019

What you need to know about non-clinical species selection

By Kirsty Harper

Traditionally, the selection of relevant species for non-clinical safety assessment has been a fairly straightforward process, with new drugs assessed in two species, typically the rat and dog.  However, with the introduction of biologics, species selection has become much more of a case by case process, and as a result target-specific pharmacology plays a critical role, for both biologics and increasingly small molecule drugs.

+ Read more
 

19 December, 2018

Top 6 pharmaceutical trends of 2018

By Freddie Campbell

The pharmaceutical market is growing at a rapid rate. 2018 produced a hive of sector activity with record-breaking FDA approvals and private investment in Biotech, all contributing to the growth of new medicines to meet unmet clinical needs.

Data shared by EvaluatePharma indicates the launch of novel therapies, including gene and cell therapies, as well as increased access to medicines globally are set to fuel growth in the market with total prescription drug sales expected to reach $1.2trn in 2024.  

With significant scientific advances in large molecular weight therapeutic development and major developments in therapeutic areas such as immunotherapies and oncology, to name a few, we've curated a set of insightful articles covering key pharmaceutical trends we saw in 2018 and things to look out for in 2019. 

+ Read more
 

05 November, 2018

5 highlights from the Annual Biologics Symposium 2018

By Rob Evans

Recently we hosted The Eighth Annual Biologics Symposium (ABS) in London where industry thought leaders discussed the development of some of the most successful, and soon to be successful, biological drugs on the market. The event was held at the state-of-the-art IET London: Savoy place, seeped in cutting edge event technology - an inspiring venue where scientists could share their ideas, network, and explore practical ways to advance their drug development goals.

+ Read more
 

26 October, 2018

Envigo Science and Technology week 2018 - helping build a healthier and safer world

By Carey Rooks

Recently Envigo held its first Science and Technology Week, across some of our key locations. We spoke to our President of EMEA Operations Lizanne Muller about this positive new program. Lizanne is based at our Huntingdon facility. She said: “Science and Technology Week was developed to celebrate the work that takes place across our organization every day. It was wonderful to see so many people sharing their passion for the work they do.” During the week we also invited our suppliers to join in our celebrations and discuss our ongoing partnerships.

+ Read more
 

03 October, 2018

How to get the most out of your preclinical CRO

By Freddie Campbell

Many industry observers have said there's no such thing as a straightforward pharmaceutical development program anymore. Rising costs, high competition, novel therapeutic targets with complex biology and an increase in regulations are all factors that contribute to the challenges of progressing drugs to the market. 

+ Read more
 

14 September, 2018

Anti-cancer evaluations with ICH S9 Guideline Q&A: what you need to know

By Robert Turcan

The ICH S9 Guideline Q&A document was recently published in June 2018, designed to clarify some of the most common challenges experienced across industry when implementing ICH S9. Here, we highlight a few key areas selected on the basis of the advice sought by our customers during development of their anticancer pharmaceutical.

+ Read more
 

03 August, 2018

Did you know the EMA has simplified the orphan drug designation application process?

By Andrea Sisneros

Every month, Envigo’s pharmaceutical regulatory team keeps track of the key changes, influences and opinions that impact the drug development process around the globe.  This month, the team discuss recent changes to the way in which the European Medicines Agency (EMA) has simplified the submission of applications for orphan drug designation.

+ Read more